Development of a Novel System for Mass Spectrometric Analysis of Cancer-Associated Fucosylation in Plasma α 1-Acid Glycoprotein

Human plasma α 1-acid glycoprotein (AGP) from cancer patients and healthy volunteers was purified by sequential application of ion-exchange columns, and N-linked glycans enzymatically released from AGP were labeled and applied to a mass spectrometer. Additionally, a novel software system for use in combination with a mass spectrometer to determine N-linked glycans in AGP was developed. A database with 607 glycans including 453 different glycan structures that were theoretically predicted to be present in AGP was prepared for designing the software called AGPAS. This AGPAS was applied to determine relative abundance of each glycan in the AGP molecules based on mass spectra. It was found that the relative abundance of fucosylated glycans in tri- and tetra-antennary structures (FUCAGP) was significantly higher in cancer patients as compared with the healthy group (P < 0.001). Furthermore, extremely elevated levels of FUCAGP were found specifically in patients with a poor prognosis but not in patients with a good prognosis. In conclusion, the present software system allowed rapid determination of the primary structures of AGP glycans. The fucosylated glycans as novel tumor markers have clinical relevance in the diagnosis and assessment of cancer progression as well as patient prognosis.

[1]  K. Kasai,et al.  Quantitative evaluation of lectin‐reactive glycoforms of α1‐acid glycoprotein using lectin affinity capillary electrophoresis with fluorescence detection , 2011, Electrophoresis.

[2]  A. Fox-Robichaud,et al.  Comparison of Methods for the Purification of Alpha-1 Acid Glycoprotein from Human Plasma , 2011, Journal of biomedicine & biotechnology.

[3]  S. Ongay,et al.  Evaluation of the effect of the immunopurification‐based procedures on the CZE‐UV and CZE‐ESI‐TOF‐MS determination of isoforms of intact α‐1‐acid glycoprotein from human serum , 2010, Electrophoresis.

[4]  S. Ongay,et al.  Development of a fast and simple immunochromatographic method to purify alpha 1-acid glycoprotein from serum for analysis of its isoforms by capillary electrophoresis. , 2010, Analytica chimica acta.

[5]  Károly Héberger,et al.  Mass spectrometric and linear discriminant analysis of N-glycans of human serum alpha-1-acid glycoprotein in cancer patients and healthy individuals. , 2008, Journal of proteomics.

[6]  Mitsuhiro Tada,et al.  BlotGlycoABC™, an Integrated Glycoblotting Technique for Rapid and Large Scale Clinical Glycomics *S , 2008, Molecular & Cellular Proteomics.

[7]  Yoshiaki Miura,et al.  Quantitative Glycomics of Human Whole Serum Glycoproteins Based on the Standardized Protocol for Liberating N-Glycans *S , 2007, Molecular & Cellular Proteomics.

[8]  F. Ceciliani,et al.  The acute phase protein alpha1-acid glycoprotein: a model for altered glycosylation during diseases. , 2007, Current protein & peptide science.

[9]  Hiroaki Nakagawa,et al.  High Throughput Quantitative Glycomics and Glycoform-focused Proteomics of Murine Dermis and Epidermis* , 2005, Molecular & Cellular Proteomics.

[10]  Y. Azuma,et al.  Glycosylation of site-specific glycans of alpha1-acid glycoprotein and alterations in acute and chronic inflammation. , 2005, Biochimica et biophysica acta.

[11]  J. Calafat,et al.  Activated human PMN synthesize and release a strongly fucosylated glycoform of α1‐acid glycoprotein, which is transiently deposited in human myocardial infarction , 2005, Journal of leukocyte biology.

[12]  H. Kuwano,et al.  α1‐Acid glycoprotein fucosylation as a marker of carcinoma progression and prognosis , 2004, Cancer.

[13]  K. Vékey,et al.  Liquid chromatographic and mass spectrometric analysis of human serum acid alpha-1-glycoprotein. , 2004, Biomedical chromatography : BMC.

[14]  M. Nakano,et al.  Detailed structural features of glycan chains derived from alpha1-acid glycoproteins of several different animals: the presence of hypersialylated, O-acetylated sialic acids but not disialyl residues. , 2004, Glycobiology.

[15]  A. Lundblad,et al.  Fucosylation of α1-acid glycoprotein (orosomucoid) compared with traditional biochemical markers of inflammation in recent onset rheumatoid arthritis , 2002 .

[16]  U. Feldt-Rasmussen,et al.  Long-term Pathologic Changes of α1-Acid Glycoprotein (orosomucoid) Glycoforms in Autoimmune Thyroid Disease , 2002, Autoimmunity.

[17]  J. Jaeken,et al.  Increased α3‐fucosylation of α1‐acid glycoprotein in patients with congenital disorder of glycosylation type IA (CDG‐Ia) , 2001 .

[18]  T. Fournier,et al.  Alpha-1-acid glycoprotein. , 2000, Biochimica et biophysica acta.

[19]  Kevin D. Smith,et al.  Modulation of sialyl Lewis X dependent binding to E-selectin by glycoforms of alpha-1-acid glycoprotein expressed in rheumatoid arthritis. , 1998, Biomedical chromatography : BMC.

[20]  T. Spector,et al.  Severe rheumatoid arthritis prohibits the pregnancy-induced decrease in α3-fucosylation of α1-acid glycoprotein , 1998, Glycoconjugate Journal.

[21]  A. Lundblad,et al.  Glycosylation of α1-acid glycoprotein in inflammatory disease: analysis by high-pH anion-exchange chromatography and concanavalin A crossed affinity immunoelectrophoresis , 1997, Glycoconjugate Journal.

[22]  J. Tillement,et al.  Two-step chromatographic purification of human plasma alpha(1)-acid glycoprotein: its application to the purification of rare phenotype samples of the protein and their study by chromatography on immobilized metal chelate affinity adsorbent. , 1996, Journal of chromatography. B, Biomedical applications.

[23]  W. Dijk,et al.  α1-Acid glycoprotein (orosomucoid): pathophysiological changes in glycosylation in relation to its function , 1995, Glycoconjugate Journal.

[24]  Peter Brouckaer.  Protection by alpha 1-acid glycoprotein against tumor necrosis factor- induced lethality , 1994, The Journal of experimental medicine.

[25]  M. Sobieska,et al.  Microheterogeneity of alpha 1-acid glycoprotein in early and established rheumatoid arthritis. , 1993, The Journal of rheumatology.

[26]  W. van Dijk,et al.  Inflammation-induced expression of sialyl Lewis X-containing glycan structures on alpha 1-acid glycoprotein (orosomucoid) in human sera , 1993, The Journal of experimental medicine.

[27]  J. Chan,et al.  One-step isolation of α1-Acid glycoprotein , 1991 .

[28]  J. Kremer,et al.  Drug binding to human alpha-1-acid glycoprotein in health and disease. , 1988, Pharmacological reviews.

[29]  J. Hansen,et al.  The microheterogeneity of alpha 1-acid glycoprotein in inflammatory lung disease, cancer of the lung and normal health. , 1984, Clinica chimica acta; international journal of clinical chemistry.

[30]  P. Arnaud,et al.  A three‐step purification of human α1‐acid glycoprotein , 1984 .

[31]  H. Gewurz,et al.  Interactions of alpha1-acid glycoprotein with the immune system. I. Purification and effects upon lymphocyte responsiveness. , 1977, Immunology.

[32]  A. Kuno,et al.  Multilectin assay for detecting fibrosis-specific glyco-alteration by means of lectin microarray. , 2011, Clinical chemistry.

[33]  A. Mackiewicz,et al.  Glycoforms of serum alpha 1-acid glycoprotein as markers of inflammation and cancer. , 1995, Glycoconjugate journal.

[34]  J. Vliegenthart,et al.  Primary structure of glycoprotein glycans , 1995 .

[35]  J. Chan,et al.  One-step isolation of alpha 1-acid glycoprotein. , 1991, Protein expression and purification.

[36]  P. Arnaud,et al.  A three-step purification of human alpha 1-acid glycoprotein. , 1984, FEBS letters.